Want to see STXS full AI Analyst Report?
STXS Stock Chart & Stats
$2.03
-$0.10(-4.18%)
At close: 4:00 PM EST
$2.03
-$0.10(-4.18%)
Day’s Range― - ―
52-Week Range$1.59 - $3.59
Previous CloseN/A
Volume282.58K
Average Volume (3M)583.61K
Market Cap
$168.11M
Enterprise Value$164.64M
Total Cash (Recent Filing)$14.62M
Total Debt (Recent Filing)$5.28M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 11, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding97,736,700
10 Day Avg. Volume380,338
30 Day Avg. Volume583,610
Financial Highlights & Ratios
PEG Ratio0.55
Price to Book (P/B)11.17
Price to Sales (P/S)6.46
P/FCF Ratio-15.18
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue5.28
Enterprise Value/Gross Profit9.80
Enterprise Value/Ebitda-8.20
Forecast
1Y Price Target
$4.13Price Target Upside103.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.18
Revenue Forecast (FY)$39.40M
Bulls Say, Bears Say
Bulls Say
Regulatory Approvals & EcosystemMultiple recent FDA approvals (MAGIC PMA, Synchrony clearance, Genesys X clearance) create a product ecosystem that materially expands the addressable market. Regulatory validation reduces clinical adoption barriers, enables broader commercial rollouts, and supports sustainable revenue streams from capital and follow-on consumables.
High‑margin Disposable Revenue PotentialInitial MAGIC procedures show high per‑procedure disposable revenue, which scales with utilization. Consumables attach rates provide recurring, high‑margin revenue that complements lumpier system sales, improving gross margin stability and long‑term cash generation as installed base and procedure volumes grow.
Strategic Acquisition And Product PipelineThe Robocath acquisition plus Genesys X and Synchrony commercialization strengthens robotics capabilities and diversifies mechanism‑of‑action across endovascular and EP markets. This broadens addressable indications (including stroke) and supports a multi‑product platform strategy that can drive longer‑term system and consumable growth.
Bears Say
Persistent Cash Burn And LossesThe company remains materially cash‑flow negative with significant TTM operating and free cash flow deficits. Continued burn forces reliance on external financing, increases execution risk for manufacturing ramps and commercialization, and constrains investment capacity until recurring revenues and margins scale materially.
Manufacturing & Supply Transition RisksSupply transition from J&J and early MAGIC production constraints have limited procedure volume and delayed disposable recognition. Persistent manufacturing or supply chain issues could slow adoption, defer high‑margin consumable revenue, and lengthen the timeline to profitable unit economics and sustainable cash generation.
Limited Liquidity And Equity ErosionA relatively small cash balance versus ongoing negative free cash flow, combined with meaningful equity erosion over prior years, raises dilution and financing risk. The company may need additional capital or nondilutive financing, which could dilute shareholders or constrain strategic flexibility during the critical ramp period.
Stereotaxis News
STXS FAQ
What was Stereotaxis’s price range in the past 12 months?
Stereotaxis lowest stock price was $1.59 and its highest was $3.59 in the past 12 months.
What is Stereotaxis’s market cap?
Stereotaxis’s market cap is $168.11M.
When is Stereotaxis’s upcoming earnings report date?
Stereotaxis’s upcoming earnings report date is Aug 11, 2026 which is in 41 days.
How were Stereotaxis’s earnings last quarter?
Stereotaxis released its earnings results on May 12, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.01.
Is Stereotaxis overvalued?
According to Wall Street analysts Stereotaxis’s price is currently Undervalued.
Does Stereotaxis pay dividends?
Stereotaxis does not currently pay dividends.
What is Stereotaxis’s EPS estimate?
Stereotaxis’s EPS estimate is -0.05.
How many shares outstanding does Stereotaxis have?
Stereotaxis has 97,736,700 shares outstanding.
What happened to Stereotaxis’s price movement after its last earnings report?
Stereotaxis reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -3.646%.
Which hedge fund is a major shareholder of Stereotaxis?
Currently, no hedge funds are holding shares in STXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stereotaxis Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.13 (103.20% Upside)
$4.13 (103.20% Upside)
Hedge Fund Trend
Increased
By 126.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.0%
Last 30 Days ▼ 6.6%
Last 30 Days ▼ 6.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.85%
12-Months-Change
Fundamentals
Return on Equity
-153.21%
Trailing 12-Months
Asset Growth
18.21%
Trailing 12-Months
Company Description
Stereotaxis
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.
STXS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced transformational strategic progress with near-term execution and financial headwinds. Major positives include multiple recent FDA approvals (MAGIC, Synchrony), successful early clinical use of the MAGIC catheter, a clear disposable revenue opportunity (disposables often >$5k–$8k per procedure), Genesys X and Synchrony commercialization steps, and the Robocath acquisition that strengthens long-term robotics strategy. Offsetting these are short-term declines in reported revenue (Q1 revenue down ~16%), capacity constraints and supply transition issues due to winding down the Johnson & Johnson relationship, continued operating losses, and increasing negative free cash flow. Management reiterated >$40M revenue guidance for 2026 and described a path to ramp and profitability, but achieving that depends on manufacturing ramp, adoption of disposables, and execution of capital sales.View all STXS earnings summariesSTXS Stock 12 Month Forecast
Average Price Target
$4.13
▲(103.20% Upside)
Technical Analysis
Atricure
―
Lemaitre Vascular
―
Merit Medical Systems
―
Staar Surgical
―
Milestone Scientific
―
Ownership Overview
20.54% Insiders
6.56% Mutual Funds
28.40% Other Institutional Investors
38.47% Public Companies and
Individual Investors